“ In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK's Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the… ”
In Conversation
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context,…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and…
